High-dose Cytarabine Plus Gemtuzumab Ozogamicin As Consolidation Therapy in Patients with Favorable- or Intermediate-Risk Acute Myeloid Leukemia
INTERNATIONAL JOURNAL OF HEMATOLOGY(2024)
摘要
Previous prospective randomized trials have investigated the efficacy of gemtuzumab ozogamicin in the frontline treatment of acute myeloid leukemia (AML). We evaluated the efficacy of high-dose cytarabine with GO as consolidation therapy in 20 patients with favorable- or intermediate-risk AML in first complete remission. They included six patients with wild-type nucleophosmin (NPM1) core binding factor (CBF), ten with NPM1-mutated non-CBF, and four with wild-type NPM1 non-CBF. The median follow-up for the entire cohort was 62.0 months. The three-year overall survival (OS) and relapse-free survival (RFS) rates were 72.2
更多查看译文
关键词
Gemtuzumab ozogamicin,Consolidation therapy,NPM1-mutated AML
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要